BioPharma Dive - Latest News

Vertex challenger Sionna prices $191M IPO

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or be used in new, multi-drug combinations.

Feb 9, 2025 - 22:25
 0
Vertex challenger Sionna prices $191M IPO

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or be used in new, multi-drug combinations.

Read More

Tags:

Previous Article

Immune drugmakers Alumis and Acelyrin to merge

Next Article

Bristol Myers, bracing for key patent losses, deepens cost-cutting plan

Related Posts

‘Fear and uncertainty’: Biotech investors warn of impact from NIH research cuts

‘Fear and uncertainty’: Biotech investors warn of impac...

Feb 25, 2025  0

The role of diagnostics in advancing antibody-drug conjugates

The role of diagnostics in advancing antibody-drug conj...

Feb 10, 2025  0

FTC case against PBMs can move forward, judge rules

FTC case against PBMs can move forward, judge rules

Feb 20, 2025  0